Earnings results for Edwards Lifesciences (NYSE:EW)
Edwards Lifesciences Corporation is estimated to report earnings on 07/22/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 12 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.55. The reported EPS for the same quarter last year was $0.34.
Edwards Lifesciences last issued its quarterly earnings data on April 19th, 2021. The medical research company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.07. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.16 billion. Its quarterly revenue was up 7.8% on a year-over-year basis. Edwards Lifesciences has generated $1.86 earnings per share over the last year and currently has a price-to-earnings ratio of 78.6. Edwards Lifesciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, July 22nd, 2021 based off prior year’s report dates.
Analyst Opinion on Edwards Lifesciences (NYSE:EW)
15 Wall Street analysts have issued ratings and price targets for Edwards Lifesciences in the last 12 months. Their average twelve-month price target is $103.00, predicting that the stock has a possible downside of 2.88%. The high price target for EW is $125.00 and the low price target for EW is $85.00. There are currently 1 sell rating, 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Edwards Lifesciences has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 11 buy ratings, 3 hold ratings, and 1 sell rating. According to analysts’ consensus price target of $103.00, Edwards Lifesciences has a forecasted downside of 2.9% from its current price of $106.05. Edwards Lifesciences has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Edwards Lifesciences (NYSE:EW)
Edwards Lifesciences does not currently pay a dividend. Edwards Lifesciences does not have a long track record of dividend growth.
Insiders buying/selling: Edwards Lifesciences (NYSE:EW)
In the past three months, Edwards Lifesciences insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,267,106.00 in company stock. Only 1.35% of the stock of Edwards Lifesciences is held by insiders. 80.29% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Edwards Lifesciences (NYSE:EW
Earnings for Edwards Lifesciences are expected to grow by 14.55% in the coming year, from $2.20 to $2.52 per share. The P/E ratio of Edwards Lifesciences is 78.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.56. The P/E ratio of Edwards Lifesciences is 78.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 39.96. Edwards Lifesciences has a PEG Ratio of 2.97. PEG Ratios above 1 indicate that a company could be overvalued. Edwards Lifesciences has a P/B Ratio of 14.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here